



Q3 2026 AI Funding by the Numbers: \$103.3B, 85% in 154 Mega-Rounds, and Europe's 75% Record

The Q3 2026 AI funding numbers do not describe one market. They describe two, and the figure that separates them is 85%.

Global AI funding fell 33% quarter over quarter to \$103.3B in Q3 2026, according to [CB Insights' State of AI Q3'26](#), published October 7, 2026. But 85% of that money went into just 154 mega-rounds, averaging roughly \$570M each and leaving about \$15.5B for every other AI company on earth. The headline drop and the concentration are the same story.

\$103.3B

global AI funding, Q3 2026, down 33% from \$153.1B in Q2
CB Insights, State of AI Q3'26, Oct 7, 2026

85%

share of that AI funding captured by 154 mega-rounds
CB Insights, State of AI Q3'26



Q3 2026 AI Funding by the Numbers: \$103.3B, 85% in 154 Mega-Rounds, and Europe's 75% Record

75%

AI's share of all European venture capital,
highest on record
Crunchbase Europe, Q3 2026

83

European companies that absorbed \$17.3B, 70%
of European VC
Crunchbase Europe, Q3 2026

In the same quarter, European AI funding set a record share: \$18.8B, or 75% of all European venture capital, per [Crunchbase's Europe report](#). Both headlines are accurate. Neither tells a seed-stage founder much, for the same reason. Crunchbase counted nearly 6,000 startups funded globally in Q3 across all sectors, with AI taking \$102B of a \$159B total, or 64% of all venture dollars. The residual after the mega-rounds is the pool that early-stage AI companies, non-AI companies, and everyone outside the top 154 names are competing over. That is the market most readers of this post actually operate in, and it is not the one the headline measures.

The 33% drop and the European record measure different things

The 33% drop is a comparison against Q2 2026's \$153.1B, a quarter inflated by its own set of outsized rounds. Quarter-over-quarter swings in a market where a handful of deals move the total by tens of billions are not trend lines. They are the arrival and non-arrival of specific transactions.

The European record is a share figure, and share figures behave differently. European startup funding reached \$25B in Q3, up 77% from \$14B in Q3 2025. AI's \$18.8B of that is a record proportion partly because AI grew and partly because non-AI European venture did not. Of the six European rounds above \$1B, five were AI-related, per [KPMG's Venture Pulse Q3'26](#): Mistral AI at \$3.5B, Helsing at \$1.8B, Quantum Systems at \$1.2B. Remove those five and the European picture looks ordinary.

The same structure shows up on the other side of the Atlantic. North American startups raised \$92B in Q3, down 35% quarter over quarter but up 50% year over year, with roughly \$61B going to AI. Down against last quarter, sharply up against last year. Both true, and both about the timing of large rounds rather than a change in investor appetite.



Q3 2026 AI Funding by the Numbers: \$103.3B, 85% in 154 Mega-Rounds, and Europe's 75% Record

! The totals do not agree with each other

CB Insights put Q3 2026 AI funding at \$103.3B. Crunchbase put AI at \$102B out of \$159B in total global venture. KPMG, using PitchBook data as of September 30, 2026, counted \$170.9B across 8,341 deals. For Europe, Crunchbase says \$25B and KPMG says \$28.4B across 1,497 deals, up from \$26.5B the prior quarter. The gaps come from different deal-inclusion rules, different cut-off dates, and different definitions of what counts as AI. Use any one of these consistently and do not mix them in the same comparison.

Late stage took 70% in Europe and early stage got \$5.7B

The European split is the clearest number in the whole dataset. Late-stage funding was \$17.3B across 83 companies, 70% of all European venture capital. Early stage came to \$5.7B, under a third of the late-stage figure, spread across the rest of the continent's startups. Eighty-three companies against several thousand.

That is the structural fact behind the record. European AI did not have a broad good quarter. Eighty-three late-stage companies had an extraordinary one, and because AI dominates the late-stage cohort, the sector-share statistic went to 75%.

The concentration is not AI-specific either. CB Insights reported total venture funding through Q3 2026 at \$698B, on pace for over \$931B for the full year, with roughly 80% of Q3 funding coming from rounds of \$100M or more. Across all of venture, four dollars in five arrived in large cheques. AI is where this pattern is most extreme, not where it originates.

Two other numbers cut against the gloom reading. Forty-two companies reached billion-dollar valuations in Q3 2026, the highest quarterly total in 18 months. And there were 35 rounds of at least \$1B globally, a record 23 of them in the United States. A quarter in which total funding falls a third while billion-dollar round counts hit records is a quarter in which capital moved up-market, not out.

MY READ

I do not think the 33% figure signals a cooling market. It signals that quarterly AI totals are now a function of whether two or three specific companies closed inside the window. When 85% of the money sits in 154 deals, the aggregate becomes a sampling artefact of a small number of decisions. I would treat any single-quarter AI funding delta under roughly 40% as noise until two consecutive quarters confirm direction. The 18-month high in billion-dollar



valuations and the record 23 US mega-rounds are harder to explain as retreat.

What the 3:1 late-stage split means if you are raising or hiring

If you are a late-stage AI company with a defensible position in model training, defence, or infrastructure, Q3 2026 was close to the best quarter available. Mistral's \$3.5B, Helsing's \$1.8B and Quantum Systems' \$1.2B are the European proof points, and the US had 23 billion-dollar rounds against Europe's six.

If you are raising a seed or Series A, none of those numbers describe your situation. The \$5.7B European early-stage pool is the relevant figure, and it is the smaller side of a 3:1 split. My reading is that capital available to early-stage AI is not shrinking so much as being measured against a late-stage total that makes it look irrelevant. That matters for expectation-setting with boards and with candidates who read the headlines.

Smaller rounds still close. [Cypher AI's \\$2M raise](#) in October went to a company building generated lab infrastructure with human approval on every write. That deal does not show up in any of the quarterly aggregates above in any visible way. Several thousand deals like it make up the long tail that the 85% statistic erases.

There is a second, less obvious consequence of concentration. Companies that raise at this scale can give away things smaller competitors sell. Reflection AI shipped [Beam, a 501B-parameter open-weight model under Apache 2.0](#), built at a \$25B valuation. If your product strategy assumes model access is a moat, check what the companies in those 154 rounds are releasing for free.

One thing I cannot resolve from this data: whether the 154 mega-rounds represent genuine capital deployment or revaluation of existing positions through insider-led rounds. The published reports give round counts and totals, not the composition of the cap tables. I would want that breakdown before drawing conclusions about how much new money entered the sector versus how much was marked up.

What is confirmed: the concentration is real and it now shows up in Europe as strongly as in




Q3 2026 AI Funding by the Numbers: \$103.3B, 85% in 154 Mega-Rounds, and Europe's 75% Record

the US. **Eighty-three companies, \$17.3B, 70% of a continent's venture capital.**

WHAT TO DO WITH THIS

Stop quoting the global AI funding number in board decks. It tracks 154 companies, not your market. Track the early-stage figure for your geography and stage (\$5.7B for Europe in Q3 2026) and the round counts rather than the dollar totals, because those totals are now dominated by a handful of transactions that have nothing to do with your fundraise. If you want a second pair of eyes on how this concentration affects your specific funding or build-versus-buy decision, [Book a call →](#)



WRITTEN BY

Artur Markus

Software engineer in Basel building AI infrastructure and agentic systems, with a background in pharmaceutical automation, GxP compliance, and validation. I help teams turn AI from a chatbot into a reliable operational layer.

[Book a meeting →](#)